Back to Agendas
[V2-S3] Promoting Clinical Development for Patients with Rare Diseases - Patient Focused Drug Development in Japan
Session Chair(s)
Kazumichi Kobayashi, RPh
Executive Deputy President (Board Member)
Otsuka Medical Devices Co., Ltd., Japan
How can new drug development reflect the Voice of Patients? EU and US are devising individual policies which meet their societies’ environment on this issue and are also intensifying “Patient Focused Drug Development (PFDD).” Meanwhile, Japan lacks assured direction on how to reflect the Voice of Patients. Reflecting this circumstance, the first speaker in this session is from a US company, who will share information on the current situation in the West and their activities regarding PFDD. After this, the subject of patient registry in intractable diseases, which is one of the possible activities for future Japan original PFDD, will be discussed, as will the current situation in Japan, issues, and contributions of medicine development from different perspectives. After the presentations, a panel discussion will seek Japan’s future direction.
Speaker(s)
Introduction of JPA(Japan Patients Association)
Tateo Ito
Japan Patients Association, Japan
President
Introduction of NPO ASrid
Yukiko Nishimura, PhD, MSc
NPO ASrid, Japan
President
Hiroshi Mizushima, PhD
National Institute of Public Health, Japan
Chief Senior Researcher, Center for Public Health Informatics
More efficient medicine development with more impact for patients with patients
Roslyn Schneider, MD, FACP
Biomarin Pharmaceuticals Inc., United States
Vice President, Head of Global Patient Affairs
Have an account?